Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

April 26, 2021

Primary Completion Date

September 23, 2025

Study Completion Date

January 2, 2026

Conditions
Human Immunodeficiency Virus 1 PositiveSkin Kaposi Sarcoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Pomalidomide

Given PO

Trial Locations (3)

Unknown

Moi University School of Medicine, Eldoret

UNC Project Malawi, Lilongwe

Uganda Cancer Institute, Kampala

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

The Emmes Company, LLC

INDUSTRY

collaborator

University of Arkansas

OTHER

collaborator

Montefiore Medical Center

OTHER

collaborator

University of Stellenbosch

OTHER

collaborator

Weill Medical College of Cornell University

OTHER

collaborator

University of California, Los Angeles

OTHER

lead

AIDS Malignancy Consortium

NETWORK